✦ LIBER ✦

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

✍ Scribed by Pienta, Kenneth J.; Machiels, Jean-Pascal; Schrijvers, Dirk; Alekseev, Boris; Shkolnik, Mikhail; Crabb, Simon J.; Li, Susan; Seetharam, Shobha; Puchalski, Thomas A.; Takimoto, Chris; Elsayed, Yusri; Dawkins, Fitzroy; Bono, Johann S.

Book ID: 115440548
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 232 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-012-9869-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A first-in-human, first-in-class, phase

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

✍ Shahneen K. Sandhu, Kyri Papadopoulos… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 298 KB

A phase 1 study of a chimeric monoclonal

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer

✍ Hudes, Gary; Tagawa, Scott T.; Whang, Young E.; Qi, Ming; Qin, Xiang; Puchalski, 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 208 KB

Randomised phase II study of siltuximab

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

✍ K. Fizazi; J.S. De Bono; A. Flechon; A. Heidenreich; E. Voog; N.B. Davis; Ming Q 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 336 KB